Restructuring |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Restructuring Costs [Abstract] | |
| Restructuring | 3. Restructuring In March 2026, the Company announced that it has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. In connection with the evaluation of strategic alternatives, the Company implemented a restructuring plan that included a workforce reduction of approximately 70%. The Company recorded restructuring costs of $0.5 million during the three months ended March 31, 2026, of which $0.4 million is included in research and development expense and $0.1 million is included in general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. Restructuring costs primarily consisted of employee severance, continuing healthcare benefits and other employee-related costs. The Company made cash payments of $0.5 million during the three months ended March 31, 2026. The remaining restructuring liability balance as of March 31, 2026 is immaterial and is expected to be paid out during the second quarter of 2026. |